Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin

Objectives The aim of this study was to report the prevalence of interferon (IFN)-associated retinopathy and other serious ocular complications in a prospectively studied group of children with chronic hepatitis C virus (HCV) receiving pegylated IFN α2b and ribavirin. Patients and methods Prospectiv...

Full description

Bibliographic Details
Main Authors: Dalia H.A.R Khalil, Hanaa M El-Karaksy, Engy Mogahed
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Journal of the Egyptian Ophthalmological Society
Subjects:
Online Access:http://www.jeos.eg.net/article.asp?issn=2090-0686;year=2016;volume=109;issue=3;spage=117;epage=121;aulast=Khalil
_version_ 1811308601029951488
author Dalia H.A.R Khalil
Hanaa M El-Karaksy
Engy Mogahed
author_facet Dalia H.A.R Khalil
Hanaa M El-Karaksy
Engy Mogahed
author_sort Dalia H.A.R Khalil
collection DOAJ
description Objectives The aim of this study was to report the prevalence of interferon (IFN)-associated retinopathy and other serious ocular complications in a prospectively studied group of children with chronic hepatitis C virus (HCV) receiving pegylated IFN α2b and ribavirin. Patients and methods Prospective comprehensive ophthalmologic examinations were performed by the first author (D.H.A.R.K.) for all included children bilaterally at 0, 12, 24, and 48 weeks after the start of treatment, and at 6 months after the end of treatment. Data recorded included visual complaints, visual acuity, pupillary reactions, and retinal findings. Results All patients aged 3–17 years who were healthy enough to participate in an ophthalmological examination were included. The number of children who remained on treatment and underwent ophthalmologic examinations was 136 after 48 weeks of treatment (90 boys and 46 girls). No patient had ischemic retinopathy at the screening eye examination before initiation of treatment. After 24 weeks of treatment, two (1.5%) patients developed anterior uveitis and another two (1.5%) patients developed retinal ischemia with cotton-wool spots. Conclusion Ophthalmologic complications are infrequent in children who are treated with pegylated IFN α2b for HCV (3%). Because of the potential severity of ischemic retinopathy and uveitis, prospective ocular assessment should remain a part of the monitoring strategy for children who are treated with IFN for HCV.
first_indexed 2024-04-13T09:26:07Z
format Article
id doaj.art-fd0e7c4f5d22436292be5106342d241b
institution Directory Open Access Journal
issn 2090-0686
2314-6648
language English
last_indexed 2024-04-13T09:26:07Z
publishDate 2016-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of the Egyptian Ophthalmological Society
spelling doaj.art-fd0e7c4f5d22436292be5106342d241b2022-12-22T02:52:27ZengWolters Kluwer Medknow PublicationsJournal of the Egyptian Ophthalmological Society2090-06862314-66482016-01-01109311712110.4103/2090-0686.202259Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirinDalia H.A.R KhalilHanaa M El-KaraksyEngy MogahedObjectives The aim of this study was to report the prevalence of interferon (IFN)-associated retinopathy and other serious ocular complications in a prospectively studied group of children with chronic hepatitis C virus (HCV) receiving pegylated IFN α2b and ribavirin. Patients and methods Prospective comprehensive ophthalmologic examinations were performed by the first author (D.H.A.R.K.) for all included children bilaterally at 0, 12, 24, and 48 weeks after the start of treatment, and at 6 months after the end of treatment. Data recorded included visual complaints, visual acuity, pupillary reactions, and retinal findings. Results All patients aged 3–17 years who were healthy enough to participate in an ophthalmological examination were included. The number of children who remained on treatment and underwent ophthalmologic examinations was 136 after 48 weeks of treatment (90 boys and 46 girls). No patient had ischemic retinopathy at the screening eye examination before initiation of treatment. After 24 weeks of treatment, two (1.5%) patients developed anterior uveitis and another two (1.5%) patients developed retinal ischemia with cotton-wool spots. Conclusion Ophthalmologic complications are infrequent in children who are treated with pegylated IFN α2b for HCV (3%). Because of the potential severity of ischemic retinopathy and uveitis, prospective ocular assessment should remain a part of the monitoring strategy for children who are treated with IFN for HCV.http://www.jeos.eg.net/article.asp?issn=2090-0686;year=2016;volume=109;issue=3;spage=117;epage=121;aulast=Khalilhepatitis Cinterferon αretinopathyribavirinuveitis
spellingShingle Dalia H.A.R Khalil
Hanaa M El-Karaksy
Engy Mogahed
Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
Journal of the Egyptian Ophthalmological Society
hepatitis C
interferon α
retinopathy
ribavirin
uveitis
title Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
title_full Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
title_fullStr Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
title_full_unstemmed Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
title_short Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
title_sort ocular manifestations in egyptian children with chronic hepatitis c treated with pegylated interferon and ribavirin
topic hepatitis C
interferon α
retinopathy
ribavirin
uveitis
url http://www.jeos.eg.net/article.asp?issn=2090-0686;year=2016;volume=109;issue=3;spage=117;epage=121;aulast=Khalil
work_keys_str_mv AT daliaharkhalil ocularmanifestationsinegyptianchildrenwithchronichepatitisctreatedwithpegylatedinterferonandribavirin
AT hanaamelkaraksy ocularmanifestationsinegyptianchildrenwithchronichepatitisctreatedwithpegylatedinterferonandribavirin
AT engymogahed ocularmanifestationsinegyptianchildrenwithchronichepatitisctreatedwithpegylatedinterferonandribavirin